This blog post was originally published by the American Association of Cancer Research (AACR) on September 16, 2014. Click here to view the original post.
Most Recent Posts
This morning, our CEO John Castellani wrote a great Morning Consult column highlighting our policy platforms supporting the prevention of prescription drug abuse, in light of the recent release of new DEA drug disposal regulations. The column is an important one for us, and expands on what other policies support the prevention of the misuse and abuse of medicines. From his column:
Every year, the federal Centers for Medicare & Medicaid Services (CMS) releases projections for national health care spending, including projections on spending for specific health care services, such as hospitalizations, physician services, health insurance premiums and administrative costs, and prescription drugs. The most recent National Health Expenditure (NHE) data, released a couple weeks ago, projects health care spending for 2013 through 2023.
While the majority (66 percent) of Americans continue to be optimistic about their health, minority communities have unique and distinct health concerns and barriers to reaching their ideal health, according to PhRMA’s Second Annual National Health Survey.
Clinical trials are the primary means of testing the safety and efficacy of new medicines. The data generated from rigorous, highly controlled trials form the basis of regulatory decisions about whether to approve the treatment for use by patients. In addition to these studies, researchers and regulators are increasingly recognizing the value of other types of research, such as observational studies. With this recognition has come a desire for greater transparency and access to the data generated from clinical trials of all types as a mea
It was like delivering a death sentence.
When HIV/AIDS cases started appearing 30 years ago, and effective ways to combat or manage the deadly disease didn't exist, dealing with a positive HIV test with a patient was a harrowing experience for physician and patient alike.
Those afflicted soon felt isolated by an epidemic fraught with myths and misunderstood by a fearful society.
But fast forward 33 years.
Looking back at the past 25 years of HIV/AIDS treatment, the progress that has been made can only be described as tremendous. Since 1995, with the development of the first protease inhibitors, the death rate in the U.S. from HIV/AIDS decreased by 83 percent.
Working with our tremendous partners in academia, research and community activism is one of the most rewarding things we do at PhRMA. This year, at the 3rd Annual Research and Hope Awards ceremony on September 10, we will celebrate the inspiring stories of individuals who have helped advance the fight against HIV/AIDS. And their efforts are worth admiring.
Astellas US President Jim Robinson said in a guest post this week, “We are on the cusp of amazing progress in U.S. biopharmaceutical research and development,” and he is right. With more than 3,400 medicines in development in the U.S., patients are seeing new treatments bring hope for the future. Thanks to innovation, we are helping more patients than ever before.
While the majority of Americans (66 percent) report they have had a good year when it comes to their personal health, that hasn’t necessarily been the case for all of us, particularly for those dealing with certain chronic health issues.
We are on the cusp of amazing progress in U.S. biopharmaceutical research and development, but without policies that help attract and retain research-based companies and partnerships to help bring new medicines to patients, we run the risk of losing our country’s competitive advantage.
Yesterday, the latest Congressional Budget Office (CBO) report was released examining projected long-term federal spending, including that of Medicare.